Allergan Sues Lupin Over Zymaxid Patents

Law360, New York (April 1, 2011, 3:39 PM EDT) -- Allergan Inc. and two Japanese pharmaceutical companies sued Lupin Ltd. in Delaware on Thursday, claiming the company's proposed generic version of pinkeye treatment Zymaxid infringes their patents.

The complaint, filed by Allergan together with Senju Pharmaceutical Co. Ltd., and Kyorin Pharmaceutical Co. Ltd. the U.S. District Court for the District of Delaware, targets Lupin’s abbreviated new drug application with the U.S. Food and Drug Administration for approval to market a generic gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis.

Zymaxid is in a class of antibiotics...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.